[FG] Fischer Dirk

Research Focus

Neurology

Area of Research

Hereditary muscle diseases, specifically research of objective imaging techniques for assessing the musculature

Approved Research Projects

• Pilot trial of metformin and L-arginine in DMD (NCT02516085)
• Pilot trial of metformin and L-citrulline in BMD (NCT02018731)
• Double blind placebo controlled of metformin and L-citrulline in DMD (NCT01995032)
• Double blind placebo controlled trial using L-Citrulline in Patients with Post-Polio Syndrome (NCT02801071)
• Observational trial of muscle function and quantitative muscle MRI in DMD
• Observational trial of muscle function and quantitative muscle MRI in BMD

Collaborations

National Collaborations

• O. Bieri (Department of Radiology, Division of Radiological Physics, University of Basel)
• R. Schläger (Department of Neurology, University Hospital Basel, University of Basel)
• OM. Dorchies (Department of Pharmacology, University of Geneva and University of Lausanne, Geneva)
• C. Bloetzer (Institute of Social and Preventive Medicine, University of Berne, Berne, Switzerland)
• Capone (Division of Pediatric Neurology, Children's Hospital, Aarau, Switzerland)
• Hoffmann-La Roche
• National patient organisations (Swiss Patient Society of muscle disease patients

International Collaborations

• G. Bernert (Department of Pediatrics, Kaiser Franz Josef Hospital, Vienna, Austria)
• V. Laugel (Department of Pediatric Neurology, Strasbourg University Hospital, Strasbourg, France)
• N. Gueven (Pharmacy, School of Medicine, University of Tasmania, Hobart, TAS, Australia)
• M. Hinton (Image Analysis Group, London, UK)
• D. Tsikas (Core Unit Proteomics, Institute of Toxicology, Hannover Medical School, Carl-Neuberg-Strass, Germany)
• C. Vuillerot (Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, L'Escale, Service de Médecine Physique et de Réadaptation Pédiatrique, Bron, France)
• International patient organisations (Duchenne UK, Duchenne Parent Project Netherlands)

Ongoing Research Projects

• Safety, tolerability and efficacy of exogenous ketone bodies for preventive treatment of migraine: A randomised, placebo-controlled, double-blind cross-over study (NCT03132233).
• Tamoxifen in Duchenne muscular dystrophy: A multicentre, randomised, double-blind, placebo-controlled, phase 3 safety and efficacy 48-week trial (NCT03354039)
• Ultrasonographic reference values for peripheral nerves and nerve roots in the normal population of children and adolescents